TY - JOUR
T1 - State-of-the art therapy for gastrointestinal stromal tumors
AU - Blanke, Charles D.
AU - Corless, Christopher L.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2005
Y1 - 2005
N2 - Until recently, there were few effective therapeutic options for patients with gastrointestinal stromal tumors (GISTs). Most patients undergoing even potentially curative resection for early-stage disease recurred if followed for a sufficiently long period, and treatment of advanced tumors with systemic chemotherapy was ineffective. Imatinib mesylate, a molecularly targeted agent that inhibits the KIT receptor tyrosine kinase, has now been demonstrated to be highly effective at inducing objective responses in GIST patients, and it improves overall survival. In locoregional disease, ongoing studies are assessing the use of imatinib pre-or postsurgery. In addition, other agents possessing activity against a variety of molecular targets are being tested in advanced disease. Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance.
AB - Until recently, there were few effective therapeutic options for patients with gastrointestinal stromal tumors (GISTs). Most patients undergoing even potentially curative resection for early-stage disease recurred if followed for a sufficiently long period, and treatment of advanced tumors with systemic chemotherapy was ineffective. Imatinib mesylate, a molecularly targeted agent that inhibits the KIT receptor tyrosine kinase, has now been demonstrated to be highly effective at inducing objective responses in GIST patients, and it improves overall survival. In locoregional disease, ongoing studies are assessing the use of imatinib pre-or postsurgery. In addition, other agents possessing activity against a variety of molecular targets are being tested in advanced disease. Questions remain about the optimal dose of imatinib, whether to continue drug in the setting of progressive disease, and how best to prevent or overcome resistance.
KW - GIST
KW - Gastrointestinal stromal tumor
KW - Imatinib mesylate
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=20044362947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20044362947&partnerID=8YFLogxK
U2 - 10.1081/CNV-200055972
DO - 10.1081/CNV-200055972
M3 - Review article
C2 - 15945512
AN - SCOPUS:20044362947
SN - 0735-7907
VL - 23
SP - 274
EP - 280
JO - Cancer Investigation
JF - Cancer Investigation
IS - 3
ER -